Related Experiment Videos
1Université de Bourgogne Franche-Comté, 21000 Dijon, France; Centre Georges-François-Leclerc, département d'oncologie médicale, 1, rue du Professeur-Marion, 21000 Dijon, France; Inserm LNC U1231, 21000 Dijon, France.
Novel Strategy In Oncoimmunology:
Recent advances in immuno-oncology with the development of anti-PD1/PD-L1 antibodies are revolutionizing oncological management. Immuno-oncology I currently developing in most histological types of cancer. However, the rate of success of anti-PD1/PD-L1 antibodies in monotherapy is limited by a limited to a subpopulation of patients accounting for about 25-30 % of patients in most indications. The development of new strategies is based on this observation with the aim to predict response or enhancing response rate. Thus, we note the development of different strategies aimed at better selecting patients or combining inhibitory checkpoints with other therapies in order to increase their effectiveness. This review will study therapeutic test strategies to validate these new associations.
Insights
Immuno-oncology therapies like anti-PD1/PD-L1 antibodies show promise but have limited success. New strategies are exploring patient selection and combination therapies to improve response rates in cancer treatment.
Area of Science:
- Oncology
- Immunology
Background:
- Anti-PD1/PD-L1 antibodies have revolutionized cancer treatment.
- Monotherapy response rates are limited to 25-30% of patients.
- Novel strategies are needed to enhance efficacy and predict response.
Purpose of the Study:
- To review therapeutic strategies for predicting and enhancing response to immuno-oncology therapies.
- To explore novel approaches in cancer treatment.
Main Methods:
- Review of current literature on immuno-oncology.
- Analysis of strategies for patient selection.
- Evaluation of combination therapies involving checkpoint inhibitors.
Main Results:
- Limited response rates in current anti-PD1/PD-L1 monotherapy.
- Development of strategies to improve patient selection.
- Emerging combination therapies show potential for increased effectiveness.
Conclusions:
- Predictive biomarkers and combination therapies are crucial for improving immuno-oncology outcomes.
- Further research is needed to validate novel therapeutic associations.